VST BIO, Corp.
June 16, 2025
Company Presentation
Brain Health
We are an advanced preclinical biotech developing a high affinity humanized antibody targeting vascular disorders related to VEGF signaling. Edema is a contributor to poor outcomes in a number of diseases in stroke, septic shock, myocardial infarction, ARIA associated disorder in Alzheimer’s disease, AMD, and others. Our antibodies do not inhibit angiogenesis or neuroprotective effects of VEGF. In an NHP stroke model, our antibody reduced vascular permeability and infarct size by 50-60%. In a rodent model, we reduced mortality in a septic shock model, and reduced cytokine storm in response to LPS. Furthermore, we have data in myocardial infarction demonstrating improved cardiac function and a dramatic reduction of interstitial fluid in response to I/R injury and post-ischemic arrhythmias. We are currently manufacturing drug for clinical trials, and are seeking a Series A.
Company HQ City:
San Diego
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
Anti-syndecan 2 antibody for stroke
CEO
Krisztina Zsebo, PhD
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
clinical proof of concept
What is your next catalyst (value inflection) update?
Q4 2026
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}